Madeline A. Zoltek

Oct 19, 2024 | biorxiv.org | Hannah Karp |Madeline A. Zoltek |KEVIN WASKO |Angel Vazquez

AbstractEffective genome editing requires a sufficient dose of CRISPR-Cas9 ribonucleoproteins (RNPs) to enter the target cell while minimizing immune responses, off-target editing and cytotoxicity. Clinical use of Cas9 RNPs currently entails electroporation into cells ex vivo, but no systematic comparison of this method to packaged RNP delivery has been made.

Sep 28, 2024 | biorxiv.org | Teresia Chen |diego rodriguez |Diego Rodríguez |Madeline A. Zoltek |Alanna Schepartz

AbstractThere is enormous interest in strategies to efficiently traffic biologics-proteins, nucleic acids, and complexes thereof-into the mammalian cell cytosol and internal organelles. Not only must these materials reach the appropriate cellular locale fully intact and in therapeutically relevant concentrations, they must also retain activity upon arrival.